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Abstract
The prevalence of metabolic syndrome (MetS) and chronic kidney dis-
ease (CKD) are increasing worldwide. Patients with these conditions are 
strongly prone to the development of and death from cardiovascular dis-
ease. Emerging data suggest that the process of development of incident 
CKD in patients with MetS is independent of that for diabetes and hyper-
tension. However, the mechanism for the emergence of CKD remains elu-
sive. Renal histopathologic changes have been recognized in MetS, 
including tubular atrophy, interstitial fibrosis, and arterial sclerosis, sug-
gesting microvascular disease. Moreover, glomerular lesions in patients 
with MetS often have greater global and segmental glomerulosclerosis. 
Studies have shown several pathways linking insulin resistance and/or 
hyperinsulinemia with incidental CKD. First, insulin resistance with com-
pensatory hyperinsulinemia promotes inappropriate activation of the renin–
angiotensin system which induces aldosterone excess and glomerular 
hypertension. Second, insulin resistance increases oxidative stress which 
has also been implicated in the renal progression of glycoxidation and 
lipid peroxidation Third, insulin resistance enhances mesangial cell prolif-
eration and extracellular matrix protein expansion via the stimulation of 
endothelin-1 and growth factors including transforming growth factor-β1 
and insulin-like growth factor-1. Finally, insulin resistance downregulates 
the renal action of peroxisome proliferator activated receptors which 
elicit foam cell formation, renal lipotoxicity and endothelial dysfunction. 
Identification of MetS may help clinicians to be aware of its components 
so that therapeutic intervention on components of MetS can be initiated 
to avoid incident CKD and further cardiovascular disease. [Tzu Chi Med J 
2010;22(1):11–17]
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1. Introduction
The epidemic prevalence of metabolic syndrome 
(MetS) and subsequent medical disorders increased 
in the late 20th century and have become significant 
issues worldwide. Furthermore, MetS has been asso-
ciated with the added risks of obesity, diabetes, cardi-
ovascular disease (CVD), and other clinical conditions, 
including peripheral and brain vascular disease, sleep 
apnea, polycystic ovarian syndrome, nonalcoholic 
steatohepatitis, gallstones, and hyperuricemia [1]. In 
Taiwan, the prevalence of MetS in one study was 12.9% 
(15.5% in men, 10.5% in women); women had a sig-
nificantly  higher tendency toward development of all 
components of MetS with age [2].
Another worldwide health issue is chronic kidney 
disease (CKD). In addition to MetS, CKD has been 
reported to be a predictor of CVD death [3]. Emerging 
data indicate that nondiabetic adults with MetS are 
prone to incident CKD, although the pathophysiology 
between these two conditions remains obscure [4]. 
Furthermore, prevention of MetS and CKD to avoid 
CVD deaths is challenging. Therefore, we will discuss 
and review the clinical evidence, renal histopathology, 
and pathogenesis of MetS in subjects who subsequently 
develop incident CKD.
2. What is metabolic syndrome?
Syndrome X, introduced by Reaven in 1988, was char-
acterized by a cluster of metabolic disturbances [5], 
including central obesity, hyperglycemia, dyslipidemia, 
and high blood pressure. Therefore, syndrome X is 
recognized to be analogous to MetS. In fact, the de-
velopment of MetS is derived from the consequences 
of insulin resistance and compensatory hyperinsuline-
mia, which have numerous causes (Table 1) [6–14]. 
The expression of insulin resistance with compensatory 
hyperinsulinemia has been found to be the result of 
complex interactions among unhealthy diets or life-
style, obesity, male sex, and genetic and environmental 
factors. Among them, central obesity may play a major 
role in triggering insulin resistance via the active adi-
pocytokine and complex pathways [12]. Furthermore, 
associated studies have suggested a genetic predis-
position to MetS, such as the genetic expression of 
adipocytokines and perilipin [14].
The mechanisms of insulin resistance with the 
consequent development of endocardiovascular dis-
ease and atherosclerosis are illustrated in Fig. 1. First, 
activation of the renin–angiotensin system (RAS) with 
subsequently elevated angiotensin II and aldosterone 
contributes to alter insulin/insulin-like growth factor-1 
signaling pathways and reactive oxygen species for-
mation to destroy endothelial function, with eventual 
development of CVD [15]. Second, the blunted actions 
of peroxisome proliferator activated receptors (PPARs) 
have been found to be important in metabolic disor-
ders and even atherosclerosis through modification of 
the innate immune system, lipotoxicity, and endothelial 
dysfunction [16]. Third, several adipocytokines have a 
central role in the regulation of insulin resistance, down-
regulation of PPARs by decreasing adiponectin, and ac-
tivation of aldosterone and inflammatory cytokines 
such as tumor necrosis factor and interleukin-6, as well 
as many aspects of endovascular atherosclerosis [17]. 
Fourth, sympathetic nerve overactivity stimulates RAS 
activity, promotes sodium reabsorption, and increases 
heart rate, stroke volume and peripheral vascular re-
sistance, thus inducing hypertension and increasing 
cardiovascular risk [18,19]. Finally, the development of 
insulin resistance has an adverse impact not only on 
endovascular disease but also on atherosclerosis.
The diagnostic criteria of MetS were redefined by 
the World Health Organization (WHO) [20], National 
Cholesterol Education Program Adult Treatment Panel 
(NCEP-ATP III) [21] and International Diabetes Federa-
tion (IDF) [22] beginning in 1998 (Table 2) [20–23]. 
The plasma fasting glucose threshold was lowered 
to 100 mg/dL in the modified NCEP-ATP III criteria. 
According to the IDF definition of MetS, the threshold 
for waist circumference is lower in Asians than in 
Europeans and varies with race. In addition, central 
obesity is an essential criterion of the IDF. In one study, 
the IDF criteria prediction of CVD was modest and sim-
ilar to other criteria, and the waist-to-hip ratio was 
strongly associated with CVD risk [24]. In Taiwan, the 
diagnostic criteria for MetS were further revised by the 
Department of Health and adopted in public health 
screening and education for related diseases [23].
3. Emerging evidence of incident 
chronic kidney disease in metabolic 
syndrome
A cross-sectional study, the Third National Health 
and Nutrition Examination Survey in the US, first de-
scribed CKD as an incident development in patients 
Table 1 — Potential causes of insulin resistance
Quality of diet
 High fructose, sucrose or glucose-enriched diets [6,7]
 High fat diets [8]
 Excessive salt diets [9]
 Ethanol diets [10]
Smoking [11]
Physical stress
Unhealthy and sedentary lifestyle
Obesity [12]
Male sex [13]
Genetic [14]
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with MetS [25]. This research showed that the odds 
ratio (OR) of CKD, defined as a glomerular filtration 
rate < 60 mL/min/1.73 m2, was 2.60 [95% confidence 
interval (CI), 1.68–4.03] in patients with MetS com-
pared with 1.89 (95% CI, 1.34–2.67) in patients with-
out MetS. The OR of CKD in patients with MetS 
increased with an increasing number of components of 
MetS, with a value of 5.85 in patients with five com-
ponents of MetS (95% CI, 3.11–11.0). In addition, 
high blood pressure was the most powerful predictor of 
CKD in patients with MetS, and the OR was 2.66 (95% 
CI, 1.62–4.35). Another prospective survey also dem-
onstrated that MetS patients have a risk of CKD (OR, 
1.88; 95% CI, 1.26–2.8), but there was no risk after 
exclusion of subjects with hypertension (OR, 0.925; 
95% CI, 0.446–1.917; p = 0.844). This further empha-
sizes the contribution of hypertension towards inci-
dent CKD [26]. These investigations suggest that MetS 
is a cluster of multiple risk factors, especially hyper-
tension, and not a unique biologic phenomenon.
A 9-year follow-up survey of 10,096 nondiabetic 
subjects in the Atherosclerosis Risk in Communities 
study reported an OR of 1.43 for the development of 
CKD among participants with MetS (95% CI, 1.18–1.73). 
The OR was 1.24 (95% CI, 1.01–1.51) after adjusting 
for the subsequent development of diabetes and hyper-
tension during the course of the study [4]. The results 
of several prospective population-based studies are 
shown in Fig. 2 [4,25–35]. It is clear that MetS pro-
motes the course of CKD even after adjustment for dia-
betes and hypertension.
Obesity, another component of MetS, has been re-
ported to predict not only CKD but also end-stage renal 
disease (ESRD). For example, obesity is solely related 
to an enhanced risk of CKD in nondiabetic and non-
hypertensive adults [36]. A high body mass index was 
associated with an increased risk of development of 
ESRD in men in the general population of Okinawa, 
Japan [37]. In addition, waist circumference, as an 
index of visceral obesity, is a more sensitive predictor 
of CKD than body mass index. For example, not only 
overweight and obese subjects, but also lean subjects 
with central fat distribution are at risk of CKD [38]. 
Similarly, weight loss in overweight patients with chronic 
proteinuric nephropathies could induce a significant 
decrease in proteinuria after bariatric surgery [39].
4. Potential histopathology and 
mechanisms of incident chronic 
kidney disease in metabolic 
syndrome
MetS is an important risk factor for proteinuria and 
chronic renal disease independent of diabetes and 
hypertension [40–43]. However, the underlying mech-
anisms have not been elucidated. Early, increasing 
urinary albumin is an indicator of hyperinsulinemic 
MetS. Nephrin, one of the glomerular podocyte pro-
teins, is critical for the action of insulin on human 
glomerular podocytes [40]. In addition, some studies 
have reported that hyperuricemia and gout precede 
Various factors
from Table 1
Insulin resistence
Hyperinsulinemia
SNS activity 
High blood glucose 
Endovascular disease
Atherosclerosis
RAS activity 
Oxidative 
stress 
Downregulate
PPARs
Adipocytokines:
 ↓ Adiponectin
 ↑ Leptin
 ↑ Resistin
High blood pressure
 ↑ Na retention
 ↓ No
 ↑ ET-1
 ↑ MMPs
 ↓ TIMP
Dyslipidemia
 ↑ TG
 ↓ HDL-C
 ↑ Dense LDL
 ↑ PP lipemia
Hyperuricemia
 ↓ Urinary uric acid
 clearance
Subclinical Clinical
Fig. 1 — A schematic of the mechanisms of insulin resistance with the consequent development of endovascular disease 
and atherosclerosis. SNS = sympathetic nervous system; RAS = renin–angiotensin system; PPARs = peroxisome prolifera-
tor activated receptors; NO = nitric oxide; ET-1 = endothelin-1; MMPs = matrix metalloproteinases; TIMP = tissue inhibitors 
of metalloproteinase; TG = triglycerides; HDL-C = high-density lipoprotein cholesterol; LDL = low-density lipoprotein; 
PP = postprandial.
14 TZU CHI MED J  March 2010  Vol 22  No 1
Table 2 — Various definitions of metabolic syndrome
 Essential criteria  No. of criteria Diagnosis
World Health Type 2 diabetes, glucose  Waist/hip ratio Essential criteria
 Organization, 1998 [20]  intolerance or insulin resistance  > 0.90 (men) + ≥ 2 No. of criteria
   > 0.85 (women) 
   or BMI ≥ 30 kg/m2 
  HDL 
   < 35 mg/dL (men) 
   < 39 mg/dL (women) 
  TG 
   ≥ 150 mg/dL 
  BP 
   ≥ 140/90 mmHg 
  Microalbuminuria 
Modified NCEP-ATP III,  Nil Waist ≥ 3 No. of criteria
 2005 [21]   ≥ 102 (men) 
   ≥ 88 (women) 
  Glucose or on drug therapy 
   ≥ 100 mg/dL 
  HDL or on drug therapy 
   < 40 mg/dL (men) 
   < 50 mg/dL (women) 
  TG or on drug therapy 
   ≥ 150 mg/dL 
  BP or on drug therapy 
   ≥ 130/85 mmHg 
IDF, 2005 [22] Waist Glucose Essential criteria
  In men  ≥ 100 mg/dL + ≥ 2 No. of criteria
  ≥ 94 cm (European) HDL 
  ≥ 90 cm (Chinese)  < 40 mg/dL (men) 
  ≥ 90 cm (South Asian)  < 50 mg/dL (women) 
  ≥ 85 cm (Japanese) TG
  In women  ≥ 150 mg/dL 
  ≥ 80 cm (European) BP 
  ≥ 80 cm (Chinese)  ≥ 130/85 mmHg 
  ≥ 80 cm (South Asian) 
  ≥ 90 cm (Japanese)  
Department of Health,  Nil Waist ≥ 3 No. of criteria
Taiwan, 2006 [23]   ≥ 90 (men) 
   ≥ 80 (women) 
  Glucose or on drug therapy 
   ≥ 100 mg/dL 
  HDL or on drug therapy 
   < 40 mg/dL (men) 
   < 50 mg/dL (women) 
  TG or on drug therapy 
   ≥ 150 mg/dL 
  BP or on drug therapy 
   ≥ 130/85 mmHg
NCEP-ATP III = National Cholesterol Education Program Adult Treatment Panel III; IDF = International Diabetes Federation; BMI = body mass index; 
HDL = high-density lipoprotein; TG = triglycerides; BP = blood pressure.
MetS with or without impaired renal function [41–43]. 
Therefore, microalbuminuria and hyperuricemia can 
be used to predict the development of MetS and 
even CKD.
Several animal studies have revealed that a high-
fat or high-fructose diet is associated with chronic 
renal disease in MetS [44–46]. A high-fat diet could 
lead to altered lipogenesis and lipolysis in the kidney, 
subsequent renal accumulation of foam cells and 
type IV collagen, an increase in urinary 8-hydroxy-2’-
deoxyguanosine and albumin excretion, and impaired 
sodium handling, as well as renal sclerosis [44–46]. 
Furthermore, a high-fructose diet can stimulate redox- 
and urate-dependent inflammatory mediators in the 
proximal tubular cells through xanthine oxidoreduct-
ase, and production of monocyte chemotactic protein 
1 and reactive oxygen species. These processes can 
lead to glomerulosclerosis and interstitial fibrosis [47].
Obesity is associated with glomerulomegaly, hyper-
filtration, proteinuria and, in extreme cases, focal 
segmental glomerulosclerosis even in the absence of 
diabetes and hypertension [48,49]. In addition, a study 
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in rats showed that consumption of a high-fructose 
diet could promote glomerular sclerosis, tubular atro-
phy, tubular dilatation, and cellular infiltration in the 
kidneys via increased renal monocyte chemoattract-
ant protein-1 [50]. Nodular glomerulosclerosis was 
reported in a patient with MetS without diabetes [51]. 
A cross-sectional study showed that patients with 
MetS have a greater prevalence of tubular atrophy, 
interstitial fibrosis, and arterial sclerosis, suggesting 
microvascular disease. Moreover, glomerular lesions 
in patients with MetS often have greater global and 
segmental glomerulosclerosis [52].
Fig. 3 shows several pathways linking insulin resist-
ance and/or hyperinsulinemia with glomerulosclerosis 
[16,53–55]. First, insulin resistance enhances the 
deleterious effects of angiotensin II in the kidney such 
as impaired pressure natriuresis, salt-sensitive high 
blood pressure, and glomerular hypertension [53]. 
Participants, n
1
Adjusted risk factor
2.6 (95% CI, 1.68–4.03)
1.24 (95% CI, 1.01–1.51)
2.08 (95% CI, 1.23–3.52)
1.537 (95% CI, 1.28–1.85)
0.93 (95% CI, 0.45–1.92)
1.86 (95% CI, 1.43–2.41)
1.332 (95% CI, 1.28–1.39)
2.03 (95% CI, 1.05–3.94)
1.3 (95% CI, 1.1–1.6)
1.53 (95% CI, 1.10–2.13)
1.83 (95% CI, 1.34–2.49)
1.680 (95% CI, 0.566–1.801)
* *
* * * *
* *
* *
* * *
* *
* *
* * * *
* *
* * * *
* * * *
* *
DM HTN Age Sex
2 3
6217
10,096
1440
6980
4607
6371
154,019
2310
2380
2764
10,685
60,921
Chen et al [25]
Kurella et al [4]
Ninomiya et al [27]
Tanaka et al [28]
Rashidi et al [26]
Tozawa et al [29]
Iseki et al [30]
Zhang et al [31]
Lucove et al [32]
Kawamoto et al [33] 
Ryu et al [34]
Chang et al [35]
Odds ratio 
Fig. 2 — Odds ratio of incident chronic kidney disease in metabolic syndrome. DM = diabetes mellitus; HTN = hyperten-
sion; CI = confidence interval.
Insulin resistance + hyperinsulinemia
Glomerulosclerosis
Activation of RAS
Angiotensin II
AT1 receptor 
Mesangial cell proliferation
Matrix protein expansion
Urinary albumin excretion
Aldosterone excess
Impaired pressure natriuresis
Increased salt sensitivity of BP
Glomerular hypertension
ET-1
IGF-1
TGF-β
Oxidative
stress
Glycoxidation
Lipid peroxidation
Downregulate
PPARs
Foam cell formation
Renal lipotoxicity
Endothelial dysfunction
ICAM-1, VCAM-1
E-selectin
IL-1, TNF-α
Fig. 3 — Pathomechanisms of insulin resistance and incident chronic kidney disease. RAS = renin–angiotensin system; 
AT1 = angiotensin II type I receptor; BP = blood pressure; ET-1 = endothelin-1; IGF-1 = insulin-like growth factor-1; 
TGF-b = transforming growth factor-b; PPARs = peroxisome proliferator activated receptors; ICAM-1 = intercellular adhe-
sion molecule-1; VCAM-1 = vascular cell adhesion molecule-1; IL-1 = interleukin-1; TNF-a = tumor necrosis factor-a.
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Second, insulin resistance increases oxidative stress, 
which has also been implicated in the renal progression 
of glycoxidation and lipid peroxidation [53]. Third, 
insulin resistance promotes the proliferation of me-
sangial cells and extracellular matrix expansion via 
stimulation from insulin itself and some growth factors 
including endothelin-1, insulin-like growth factor-1 and 
transforming growth factor-β [54]. Finally, insulin re-
sistance downregulates the renal action of PPARs which 
elicit foam cell formation, renal lipotoxicity and en-
dothelial dysfunction from the co-effects of intercel-
lular adhesion molecule-1, vascular cell adhesion 
molecule-1, E-selectin and some cytokines such as 
interleukin-1 and tumor necrosis factor-α [16,55].
5. Conclusion
MetS leads to the development of CKD independent of 
diabetes and hypertension. Renal histopathologic 
changes have been recognized in MetS patients, in-
cluding tubular atrophy, interstitial fibrosis, and arterial 
sclerosis, suggesting microvascular disease. The patho-
genesis of insulin resistance and/or hyperinsulinemia 
in the development of incidental CKD involves insu-
lin resistance with compensatory hyperinsulinemia, 
which can activate the RAS, increase oxidative stress, 
stimulate endothelin-1 and growth factors (transform-
ing growth factor-β1 and insulin-like growth factor-1), 
and downregulate the renal action of PPARs. Iden-
tification of MetS may help clinicians to be aware of its 
components so that therapeutic intervention on 
MetS components can be initiated to avoid incident 
CKD and further CVD.
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